Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded tumor blocks was used to identify candidate prognostic genes (N=432). Second, a focused gene expression assay including prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N=186). Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N=216). The GCPS was validated in another set with stage II GC who underwent surgery without adjuvant treatment (N=300). GCPS was developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of validation cohort treated with chemoradiotherapy (N=216) as high-risk group with 5-year recurrence rate of 58.6% compared to 85.4% in the low risk group (hazard ratio for recurrence=3.16, p=0.00004). GCPS also identified high-risk group among stage II patients treated with surgery only (hazard ratio=1.77, p=0.0053).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066 · cited 1×
“For nCounter assay, 200 ng of total RNA was hybridized with the custom designed code set of 800 genes for 18 hours at 65uC and processed according to manufacturer’s instruction [12].”
MethodGene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Cited by
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223
Self-citationDevelopment and verification of the PAM50-based Prosigna breast cancer gene signature assay
Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., Snider, J., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0129-6 · Cited by 542
Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma
Tan, P., & Yeoh, K.-G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.059 · Cited by 492
Self-citationSohn, B. H., Hwang, J.-E., Jang, H.-J., Lee, H.-S., Oh, S. C., Shim, J.-J., Lee, K.-W., Kim, E. H., Yim, S. Y., Lee, S. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2211 · Cited by 489
Self-citationClinical and genomic landscape of gastric cancer with a mesenchymal phenotype
Oh, S. C., Sohn, B. H., Cheong, J.-H., Kim, S.-B., Lee, J. E., Park, K. C., Lee, S. H., Park, J.-L., Park, Y.-Y., Lee, H.-S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04179-8 · Cited by 424
Self-citationMolecular classification of gastric cancer
Chia, N.-Y., & Tan, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw040 · Cited by 375
Self-citationVeldman-Jones, M. H., Brant, R., Rooney, C., Geh, C., Emery, H., Harbron, C. G., Wappett, M., Sharpe, A., Dymond, M., Barrett, J. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0262 · Cited by 328
Ham, I.-H., Oh, H. J., Jin, H., Bae, C. A., Jeon, S.-M., Choi, K. S., Son, S.-Y., Han, S.-U., Brekken, R. A., Lee, D., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0972-8 · Cited by 264
Update on gastric cancer treatments and gene therapies
Biagioni, A., Skalamera, I., Peri, S., Schiavone, N., Cianchi, F., Giommoni, E., Magnelli, L., & Papucci, L. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09803-7 · Cited by 183
“New genomic technologies such as the NanoString nCounter system have been used in several clinical trial studies for prognostic and predictive markers [74].”
MethodADAMTS12 acts as a tumor microenvironment related cancer promoter in gastric cancer
Hou, Y., Xu, Y., & Wu, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-90330-3 · Cited by 19
Chen, S., Zang, Y., Xu, B., Lu, B., Ma, R., Miao, P., & Chen, B. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5844846 · Cited by 15
Consensus molecular subtype transition during progression of colorectal cancer
van de Weerd, S., Torang, A., Zwager, L. W., Koelink, P. J., Koster, J., Bastiaansen, B. A., Lammers, V., Longobardi, C., Roodhart, J. M., van Krieken, J. H., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6176 · Cited by 6
“The NanoString platform is a reliable and robust platform for samples with partly degraded RNA [25 – 27].”
Background
Metadata
- Authors
- Lee, J., Sohn, I., Do, I.-G., Kim, K.-M., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Sohn, T. S., Bae, J. M., Choi, M. G., Lim, D. H., Min, B. H., Lee, J. H., Rhee, P. L., Kim, J. J., Choi, D. I., Tan, I. B., Das, K., Tan, P., Jung, S. H., Kang, W. K., & Kim, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-05
- Volume
- 9
- Issue
- 3
- Pages
- e90133
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2015162631
- Cited by
- 141
- References
- 2
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.